Persistent efficacy of doramectin against experimental challenge with Ostertagia ostertagi in cattle.
Two studies were conducted in North America to evaluate the persistent efficacy of doramectin injectable solution against experimental challenge with infective larvae of Ostertagia ostertagi. In both studies, four groups of 10 randomly-assigned calves, negative for trichostrongyle-type eggs on fecal examination, were treated subcutaneously in the midline of the neck with saline (1 ml 50 kg-1) on Day 0 or doramectin (200 micrograms kg-1 = 1 ml 50 kg-1) on Day 0, 7, or 14. Two additional calves from the same pool of animals were randomly assigned as larval-viability monitors and received no treatment. Beginning on Day 14 and continuing through Day 28, the 40 treated calves each were given approximately 1000 infective larvae of O. ostertagi by gavage daily; the two larval-viability monitors were inoculated in a similar manner with approximately 30,000 larvae as a single dose on Day 28. Animals were slaughtered on Day 42 in one study and on Days 42, 43, or 46 in the second. The abomasum from each calf was harvested and processed for worm recovery. A 2% aliquot of abomasal contents plus wash was examined for worm quantification and identification. Geometric mean O. ostertagi burdens were calculated from the log (O. ostertagi count + 1) and were used to estimate percentage reduction. In both studies, doramectin injectable solution was > or = 99.6% efficacious in reducing infection resulting from challenge with infective larvae of O. ostertagi for at least 21 days posttreatment; by 28 days posttreatment, efficacy was 87.3% in one study and 99.7% in the other.
Conder
G A
GA
Pfizer Central Research, Groton, CT 06340, USA.
Cruthers
L R
LR
Slone
R L
RL
Johnson
E G
EG
Zimmerman
G L
GL
Zimmerman
L A
LA
Shively
J E
JE
Logan
N B
NB
Weatherley
A J
AJ
D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D002417:Cattle; D002418:Cattle Diseases; D005243:Feces / Q000469:parasitology; D005260:Female; D007559:Ivermectin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007814:Larva; D008297:Male; D009919:Orchiectomy; D010028:Ostertagia / Q000302:isolation & purification; D010029:Ostertagiasis / Q000188:drug therapy / Q000662:veterinary*; D010270:Parasite Egg Count
D000871:Anthelmintics; D007559:Ivermectin; C084101:doramectin